Clinical Trial Update: Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating 90Yttrium-epratuzumab for CD22-positive relapsed/refractory B-cell acute lymphoblastic leukemia in adults has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• 90Yttrium-epratuzumab (epratuzumab (Yttrium-90 labeled))

Snippet

Sponsor: Nantes University Hospital | Conditions: CD22+ Relapsed/Refractory B-ALL | Phase 2 | Status: WITHDRAWN